Global pharma giants turn to Chinese biotech to tap innovation, valuation growth

Global pharmaceutical giants are doubling down on investing in China’s fast-growing biotech companies given the sector’s huge room for valuation growth, according to speakers at the Global Health Summit, which concluded in Hong Kong on Saturday.

This is a short excerpt. EkJhalak links out rather than reproducing other newsrooms’ work — continue at South China Morning Post.